Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

As with the NMOSD-focused film, “Rare Connections in gMG” is aimed at countering the “relatively low” awareness of the rare disease, according to Christophe Hotermans, M.D., Ph.D., Alexion’s head of ...

As for its neuroscience portfolio, AbbVie has added $300 million, putting its projection for the year at $10.5 billion, which ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...

But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...

Evotec has inked a deal to sell its biologics manufacturing facility in Toulouse, France, to generics giant Sandoz for around ...

The first commercial for Johnson & Johnson and Legend Biotech’s Carvykti focuses on the numbers that make up a multiple ...

As Celltrion looks to ward off potential import tariffs, the South Korean company’s odds of acquiring a large-scale drug ...

Freshly appointed Center for Drug Evaluation and Research (CDER) leader George Tidmarsh M.D., Ph.D., will now take on the role of acting director of CBER as well, according to an internal letter from ...